NEWS
2024 A Shared Lifetime of Giving Back to Einstein
2024 Trademark "TOP CAR" [TMIGD2 optimized potent/persistent (TOP) chimeric antigen receptor (CAR)] was granted
2024 Patent [#12,145,989; Antagonist Monoclonal Antibodies against Human Immune Checkpoint CEACAM1 (CD66a) and Formulations, Kits, and Methods of Use Thereof] was granted.
2024 Patent (Monoclonal Antibodies against Human Tim-3) was granted
2024 科学家开发新型CAR-T细胞疗法，为实体肿瘤治疗开辟新路径
2024 研究者らはCAR-T細胞を増強して固形腫瘍を標的にしている
2024 La revolucionaria terapia celular CAR-T busca abrirse paso más allá del cáncer de la sangre
2024 CAR-T治疗实体肿瘤有了新突破
2024 Strengthening CAR-T therapy to work against solid tumors
2024 Our new CAR therapy research was covered by 48 news articles worldwide
2024 Based entirely on our lab's research, a new drug company is established to develop novel first-in-class immunotherapies
2024 Technology Networks: The Next Chapter of Science
2024 The Next Breakthrough Against Cancer?
2024 Endpoints News: Ivan Cheung's post-Eisai life takes hold at NextPoint Therapeutics
2024 Promising new therapy for a hard-to-treat blood cancer
2023 Novel immunotherapy target for breast cancer
2023 Fibroblasts found to promote Glioblastoma tumors
2023 Working with Einstein's OBBD: Know when it's time
2023 A novel immune checkpoint inhibitor TQB2618 from our lab started two new clinical trials: TQB2618 + anti-PD1 + Anlotinib Hydrochloride Capsules as first-line treatment in 40 patients with advanced hepatocellular carcinoma and in 75 patients with advanced colorectal cancer.
2023 First Patient for NPX267 Program. NPX267, originally generated in our lab and a first-in-class drug, starts phase I, multicenter, first-in-human clinical trial in six medical centers including Massachusetts General Hospital, MD Anderson Cancer Center, Johns Hopkins University, Montefiore Einstein Cancer Center, Sarah Cannon Research Institute, and NEXT Oncology-San Antonio. The trial includes 131 patients with 12 different types of metastatic solid cancers, including renal cell carcinoma, non-small cell lung cancer, cholangiocarcinoma, colorectal cancer, pancreatic cancer, urothelial carcinoma, gastric gastroesophageal carcinoma, triple negative breast carcinoma, endometrial cancer, cervical cancer, osteosarcoma, and prostate cancer.
2023 Investigational New Drug (IND) application of a first-in-class immune checkpoint inhibitor from our lab received U.S. Food and Drug Administration (FDA) clearance for the first-in-human trial.
2023 How To Turn T Cells Loose. TQB2618, originally generated in our lab, is currently in several phase II and phase I/II clinical trials in 580 patients with 6 different types of advanced solid cancers (nasopharyngeal cancer, non-small cell lung cancer, small cell lung cancer, esophageal cancer, head and neck cancer, melanoma) and 3 different types of recurrent/refractory hematologic cancers (acute myeloid leukemia, myelodysplastic syndromes, lymphoma).
2023 A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1 and chemotherapy, in first-line treatment of 60 patients with relapsed/metastatic head and neck squamous cell carcinoma.
2023 A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1 and chemotherapy, in 75 patients with relapsed/metastatic esophageal squamous cell carcinoma.
2023 Endpoints News: Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise
2023 Developing Novel Checkpoint Inhibitors Against Bladder Cancer
2022 Our new immune checkpoint discovery was covered by 68 news articles in 7 languages worldwide
2022 GEN: First-In-Class Immune Checkpoint Therapy Unlocks NK Cell Attack on Tumors
2022 Cancro: promettente nuova terapia sviluppata dall’Albert Einstein College of Medicine
2022 El Confidencial: Las nuevas 'células asesinas' contra el cáncer que pueden cambiarlo todo
2022 Einstein Researchers Develop Promising New Cancer Therapy
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-L1, to treat 115 patients with non-small cell lung cancer.
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-L1, to treat 55 patients with small cell lung cancer.
2022 A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1, to treat 90 patients with relapsed and refractory lymphoma.
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with demethylation drugs (Azacitidine, Decitabine), to treat 70 patients with recurrent/refractory acute myeloid leukemia (AML), myelodysplastic syndromes (MDS).
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-1, to treat 50 patients with advanced melanoma.
2022 Overcoming Resistance to Checkpoint Inhibitor Cancer Therapy.
2022 Checkpoint Protein's Unexpected Role in Fat Metabolism.
2022 Patent was granted.
2021 肿瘤免疫学家臧星星教授: 站在世界药物研发最前列, 展望KIR3DL3-HHLA2新免疫检查点
2021 Promising New Cancer Immunotherapy Drug.
2021 Freeing Immune Cells to Combat Cancer.
2020 A novel immune checkpoint inhibitor derived from our lab started clinical trial to treat 50 cancer patients with advanced solid tumors who had failed standard treatments or lack effective treatments.
2020 Cancer Research Institute CLIP Investigator.
2020 Patent (B7x and Its Derivatives for Treating and Preventing Cardiovascular Disease) was granted.
2019 A new drug company is established based on our research: NextPoint Therapeutics.
2019 MD-PhD student Peter John wins Lasker Essay Contest.
2019 MD/PhD Candidate Makes His Mark on Cancer Research and Bronx Kids' Program.
2018 Patent (HHLA2 as a Novel Inhibitor of Human Immune System and Uses Thereof) was granted.
2018 MD-PhD student Peter John received F30 Individual Predoctoral Fellowship Award from National Institutes of Health.
2017 Zang lab new immunotherapy technologies were licensed to a biotech company in California.
2017 A new pharmaceutical company was established based on our research.
2017 The Zang lab/Einstein and Chia Tai Tianqing Pharmaceutical Group signed an agreement to develop new immunotherapy drugs.
2016 MD-PhD student Jordan Chinai received the first Barry R. Bloom Speaker Award.
2015 Xingxing Zang received Lustgarten-eBioscience Memorial Award, American Association of Immunologists.
2015 The Zang lab and Pfizer to jointly develop novel drugs for treating human cancers.
2015 Developing Type 1 Diabetes Therapies.
2015 Congressionally Directed Medical Research Programs.
2014 Drs. Xingxing Zang, Steven Almo and Stanley Nathenson
2014 MD-PhD student Kim Ohaegbulam received NRSA F31 Individual Predoctoral Fellowship Award from National Institutes of Health.
2014 Hitting Them with Her Best Shot: An Einstein Alum Talks to Kids about Vaccines.
2013 Our new cancer immunotherapy technology was licensed to a pharmaceutical company.
2013 MD-PhD student Kim Ohaegbulam was invited as a Keynote Speaker for the Annual Moffitt Student Research Day at the Moffitt Cancer Center, Florida.
2013 Regulating Human Immune Response
2008 Xingxing Zang received NIH Director’s New Innovator Award (NIH Type 1 Diabetes Pathfinder Award).